Use of carbostyril to increase somatostatin or for inhibiting decrease of somatostatin to treat diseases related thereto
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorsKatsuya Yamasaki, Kazushi Sakurai
Life of this patent
Estimating the term…
Abstract
An agent for increasing secretion of somatostatin or inhibiting decrease of secretion of somatostatin which comprises as an active ingredient a carbostyril compound of the formula: ##STR1## or a salt thereof, which is useful for treating diseases associated with the decrease of somatostatin such as esophagitis, Alzheimer's disease, etc.
Claims2
A method for treating a subject afflicted with a disease associated with a decrease of somatostatin selected from the group consisting of esophagistis, Zollinger-Ellison syndrome, diarrhea, erethistic colitis, hepatitis, portal hypertension, headache, migraine, Alzheimer's disease, presbyophrenia, pancreatitis and acromegalia, which comprises administering an effective amount of a carbostyril compound of the following formula which increases the secretion of somatostatin or inhibits the decrease of secretion of somatostatin:
- ##STR3## wherein R is a halogen atom, and the propionic acid substituent is substituted at the 3- or 4-position on the carbostyril nucleus, and the bond between the 3- and 4-positions is a single or double bond, or a pharmaceutical acceptable salt thereof.
Dependencies are inferred from the claim text.